This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York